| Literature DB >> 19015750 |
Wendy K W Yap1, Suhaila Mohamed, Mohammad Husni Jamal, Meyer Diederick, Yazid A Manap.
Abstract
The effects of inulin on the microbial composition and faecal characteristics in 36 healthy, formula-fed infants (average age 7.7 months) given 3 different daily dosages of native inulin (0.75 g/day, 1.00 g/day, and 1.25 g/day) were studied. At all levels of inulin consumption, a significant (p<0.05) reduction of potential pathogenic microorganisms such as clostridia was found. An intake of 1.25 g/day of inulin caused a significant (p<0.05) increase of Bifidobacterium spp. as well as a significant (p<0.05) decline in Gram-positive cocci and coliform bacteria. Inulin consumption resulted in a significant (p<0.05) decrease in faecal pH value and changes in faecal weight, faecal texture and colour, indicating improvement in healthy bile production and bacterial fermentation. It is concluded that inulin consumption in formula-fed infants after weaning positively affected the microbial composition of faeces and faecal properties.Entities:
Keywords: formula-fed; infants; inulin; microbiota; stool properties
Year: 2008 PMID: 19015750 PMCID: PMC2581760 DOI: 10.3164/jcbn.2008055
Source DB: PubMed Journal: J Clin Biochem Nutr ISSN: 0912-0009 Impact factor: 3.114
Faecal microbial composition during various treatment periods
| Bacteria | Group | Bacteria in Log10 cfu/g (±SD) during | ||
|---|---|---|---|---|
| Basal period | Inulin period | Washout period | ||
| Total anaerobes | I ( | 10.57 ± 0.35 | 10.73 ± 0.29 | 10.15 ± 0.44 |
| II ( | 10.34 ± 0.18 | 9.89 ± 0.83 | 10.50 ± 0.25 | |
| III ( | 10.28 ± 0.35 | 9.67 ± 0.30* | 10.10 ± 0.12 | |
| IV ( | 10.45 ± 0.35 | 10.46 ± 0.30 | 10.43 ± 0.35 | |
| Bifidobacteria | I ( | 9.16 ± 0.57 | 9.36 ± 0.58 | 8.91 ± 0.51 |
| II ( | 9.64 ± 0.28 | 9.77 ± 0.38 | 9.83 ± 0.26 | |
| III ( | 9.23 ± 0.38 | 9.55 ± 0.17* | 9.56 ± 0.34 | |
| IV ( | 9.05 ± 0.41 | 9.04 ± 0.32 | 9.32 ± 0.39 | |
| Lactobacilli | I ( | 8.61 ± 0.93 | 8.90 ± 0.68 | 8.70 ± 0.56 |
| II ( | 9.61 ± 0.15 | 8.86 ± 0.15* | 9.31 ± 0.19 | |
| III ( | 8.78 ± 0.43 | 8.15 ± 0.75 | 8.20 ± 0.71 | |
| IV ( | 5.92 ± 0.51 | 5.01 ± 0.52 | 6.13 ± 0.43 | |
| Coliforms | I ( | 8.51 ± 0.38 | 8.44 ± 0.58 | 9.23 ± 0.61 |
| II ( | 8.85 ± 0.69 | 8.50 ± 0.46 | 8.79 ± 0.47 | |
| III ( | 9.68 ± 0.32 | 8.13 ± 0.40* | 8.80 ± 0.49 | |
| IV ( | 9.22 ± 0.35 | 9.26 ± 0.52 | 9.41 ± 0.56 | |
| Clostridia | I ( | 10.15 ± 0.15 | 9.28 ± 0.35* | 9.34 + 0.55 |
| II ( | 9.98 ± 0.32 | 8.95 ± 0.20* | 10.20 + 0.35 | |
| III ( | 9.66 ± 0.32 | 8.78 ± 0.39* | 9.59 + 0.25 | |
| IV ( | 9.87 ± 0.24 | 9.88 ± 0.23 | 9.89 ± 0.25 | |
| Gram-positive cocci | I ( | 9.76 ± 0.71 | 8.74 ± 0.55* | 8.78 ± 0.55 |
| II ( | 9.38 ± 0.62 | 8.88 ± 0.27 | 10.04 ± 0.42 | |
| III ( | 9.12 ± 0.42 | 8.42 ± 0.28* | 9.10 ± 0.67 | |
| IV ( | 9.05 ± 0.53 | 9.21 ± 0.44 | 9.66 ± 0.59 | |
Group I: 0.75 g/d of inulin during supplementation, Group II: 1.00 g/d of inulin; Group III: 1.25 g/d of inulin. Group IV: 0 g/d of inulin. Each group serve as their own control. Significant differences between groups for lactobacillus and bifidobacteria at basal period, were unexpected, since the babies were distributed randomly without any prior knowledge of their faecal microbiota profile. All babies were from the same area of residence.
*Significant changes as compared to basal period (p<0.05) during inulin supplementation
Fig. 1Increase in Bifidobacterium sp. as a function of the initial number of Bifidobacterium sp. at various levels of inulin supplementation. The faecal content of Bifidobacterium sp. was determined with and without inulin supplementation of the diet, and the logarithmic increase was calculated. The line is the best fit as calculated (by Excel).
Faecal characteristics
| Parameter | Group | Basal period | Inulin period | Washout period |
|---|---|---|---|---|
| Faecal pH | I ( | 6.8 ± 0.5 | 6.7 ± 0.6 | 6.9 ± 0.7 |
| II ( | 6.8 ± 0.6 | 6.3 ± 0.5* | 6.6 ± 0.4 | |
| III ( | 6.7 ± 0.7 | 5.9 ± 0.3* | 6.4 ± 0.6 | |
| IV ( | 7.1 ± 0.6 | 7.2 ± 0.4 | 7.4 ± 0.5 | |
| Defecation frequency (per day) | I ( | 1.07 ± 0.25 | 1.13 ± 0.25 | 1.33 ± 0.15 |
| II ( | 1.28 ± 0.13 | 1.22 ± 0.18 | 1.17 ± 0.17 | |
| III ( | 1.56 ± 0.17 | 1.48 ± 0.15 | 1.52 ± 0.15 | |
| IV ( | 1.11 ± 0.19 | 1.12 ± 0.20 | 1.19 ± 0.23 | |
| Faecal mass (g/day) | I ( | 43.9 ± 12.8 | 55.8 ± 14.8 | 57.2 ± 12.8 |
| II ( | 44.2 ± 11.6 | 49.7 ± 13.8 | 48.5 ± 10.6 | |
| III ( | 54.3 ± 14.1 | 58.0 ± 11.4 | 51.3 ± 14.1 | |
| IV ( | 44.1 ± 12.9 | 44.2 ± 12.7 | 44.4 ± 12.6 | |
| Faecal consistency | I ( | 2.9 ± 3.7 | 2.4 ± 3.9 | 2.8 ± 4.2 |
| [scored from 1: watery–5: hard pellets ] | II ( | 2.3 ± 2.6 | 2.0 ± 2.7 | 1.9 ± 3.2 |
| III ( | 2.6 ± 4.2 | 2.1 ± 3.7 | 2.2 ± 4.2 | |
| IV ( | 2.7 ± 3.8 | 2.8 ± 3.6 | 2.6 ± 3.9 |
Group I: 0.75 g/d of inulin during supplementation, Group II: 1.00 g/d of inulin; Group III: 1.25 g/d of inulin. Group IV: 0 g/d of inulin. All data are given as the average ± SD. *Significant changes as compared to basal period (p<0.05) during inulin supplementation.
Fig. 2Faecal colour during basal, treatment and washout periods in the various infants given different levels of inulin supplementation.
A: Infants treated with 0.75 g/day inulin showed an increase in brown stools and a reduction in yellow/greenish stool during treatment period. During the washout period, the number of brown stools decreased, while that of the yellow/greenish stool increased again. Infants not given any inulin showed no significant change in stools colour profile.
B: Infants treated with 1.00 g/day inulin also showed increase in the number of brown stools and a reduction in yellow/greenish stool during treatment. Again, during the washout period, the number of brown stools decreased, while that of the yellow/greenish stool increased.
C: Infants treated with 1.25 g/day inulin showed insignificant changes in stools colour during treatment, followed by a significant increase in brown stools and a significant reduction in golden stool during the washout period.
Dagger: Significantly different (p<0.05) from basal
Open circle: Significantly different (p<0.05) from treatment